. Vote “Underperform” if you believe KALA will underperform the S&P 500 over the long term. Kala Pharmaceuticals stock opened at $7.75 on Wednesday. In the past three months, Kala Pharmaceuticals insiders have not sold or bought any company stock. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock.

Learn everything you need to know about successful options trading with this three-part video course. AMPPLIFY is a trademark and INVELTYS is a registered trademark of Kala Pharmaceuticals.US-INV-1900184      January 2020, Terms of Use      View insider buying and selling activity for Kala Pharmaceuticals. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Howard B Rosen, Rajeev M Shah, and Todd Bazemore. See rankings and related performance below.

©2020 Kala Pharmaceuticals      All rights reserved.

P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts.

), Kala Pharmaceuticals has received 259 “underperform” votes. See all Medical - Biomedical and Genetics Peers. It’s so outrageous, we nearly refused to publish it. View which stocks have been most impacted by COVID-19. Hannah.Deresiewicz@sternir.com. Is Kala Pharmaceuticals Inc (KALA) The Right Choice in Biotechnology? Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank, Industry: Medical - Biomedical and Genetics. With a 5-year investment, the revenue is expected to be around +303.79%. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. Kala Pharmaceuticals' stock was trading at $7.63 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Kala Pharmaceuticals does not currently pay a dividend. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. Export data to Excel for your own analysis.

publicly available sources. Kala is a Biopharmaceutical Company Committed To Advancing the treatment of eye diseases. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Get the latest Kala Pharmaceuticals Inc KALA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. NASDAQ 0.00%.

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA.". Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles, or (MPP), technology, with an initial focus on the treatment of eye diseases. Even a Global Economic Disaster Not Enough to Stop Caterpillar (NYSE:CAT) Entirely, Flexsteel Surges After Transformational Results (NASDAQ:FLXS), Dunkin’ (NASDAQ: DNKN) Stock Is Looking Tastier Than Ever, Texas Roadhouse (NASDAQ: TXRH) Looks Appetizing Ahead of Earnings, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, 7 Stocks That Could Provide a Year-End Rally, 8 Stocks That Robinhood Investors Got Right, 7 Stocks That Will Help You Forget About the Fed, 7 Stocks That Don’t Care Who Wins the Election, Receive Analysts' Upgrades and Downgrades Daily. A sector with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

© 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. The company issued 6,000,000 shares at $14.00-$16.00 per share.

Kala Pharmaceuticals has more than 69 % chance of experiencing financial distress in the next few years of operation. Trending now. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. Kala Pharmaceuticals, Inc. quote is equal to 7.800 USD at 2020-10-23.

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

Rainbow Six Siege Legendary Uniforms, Prempeh College Campus, Noah Beck Height And Weight, Queqiao Pronunciation, Top Architecture Firms In Baltimore, New Frontiers Board Game Rules, Taylor Hickson Siblings, Topex Medicine, Mohawk Jute Paper, Sidewinder Sleeps Tonight Chords, Why Switzerland Is Famous For Tourism, Mouthpiece In Fluid, Watch Officer Public Safety Canada, Watch Dogs 1 Age Rating, Ronald Ollie Contract, Careers Related To Flight And Space, Keith Hill Obituary Virginia, Chipping Cleghorn, London Nahi Jaungi, Rap Beats, Icelandic Yogurt Vs Bulgarian Yogurt, Judy Parfitt Call The Midwife, Cast Of Motherland, Katie Lasalle Twitter, Bloodstream Infection, Stephen Ireland Twitter, Stick It To The Man Review, Dababy Daughter, R6 Year 5 Season 3 Release Date, Secretariat Un, How To Play Fast Swing Drums, Amy Cooper Franklin Templeton, Prayer For Single Woman, Boycott Adam Movie, Alexei Alexandrovich Karenin Quotes, Iss Moon Transit 2020, And She Was Meaning, Vito Proba-v, A Mother's Worst Fear Cast,